Prostate Cancer Clinical Trial
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
Summary
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years old.
Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
Clinical Stage T2b - T2c (AJCC 6th edition) tumor
Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
Clinical stage T3 or T4 (AJCC 6th edition) tumor
Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
Bleeding hemorrhoids requiring medical intervention within the prior three months.
Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
Unable to comply with the study requirements or follow-up schedule.
Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
Known iodine sensitivity or allergy
Known polyethylene glycol (PEG) sensitivity or allergy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 27 Locations for this study
Fort Myers Florida, 33908, United States
Lakewood Ranch Florida, 34202, United States More Info
Principal Investigator
Tampa Florida, 33609, United States More Info
Principal Investigator
Kansas City Kansas, 66160, United States
Troy Michigan, 48098, United States More Info
Principal Investigator
Bloomfield New Jersey, 07003, United States More Info
Principal Investigator
Pittsburgh Pennsylvania, 15232, United States More Info
Principal Investigator
Waratah New South Wales, 2298, Australia More Info
Principal Investigator
Woolloongabba Queensland, 4102, Australia More Info
Principal Investigator
Nedlands Western Australia, 6009, Australia More Info
Principal Investigator
Villejuif Cedex, 94805, France More Info
Principal Investigator
Bonn , D-531, Germany More Info
Principal Investigator
Nürnberg , 90419, Germany More Info
Principal Investigator
Cork , T12 D, Ireland More Info
Principal Investigator
Parma , 43126, Italy More Info
Principal Investigator
Verona , 37024, Italy More Info
Principal Investigator
Barakaldo , 48903, Spain More Info
Principal Investigator
Madrid , 28002, Spain More Info
Principal Investigator
Madrid , , Spain More Info
Principal Investigator
Basel , CH-40, Switzerland More Info
Principal Investigator
Bern , 3010, Switzerland More Info
Principal Investigator
Guildford Surrey, GU27X, United Kingdom More Info
Principal Investigator
Cardiff Wales, CF14 , United Kingdom More Info
Principal Investigator
Belfast , BT9 7, United Kingdom More Info
Principal Investigator
Bristol , BS2 8, United Kingdom More Info
Principal Investigator
London , SW3 6, United Kingdom More Info
Principal Investigator
Norwich , NR4 7, United Kingdom More Info
Principal Investigator
Plymouth , PL6 8, United Kingdom More Info
Principal Investigator
How clear is this clinincal trial information?